Medicenna Announces Oral Presentation of New Bizaxofusp Results at SNO 2026

TORONTO and HOUSTON, Sept. 24, 2026 /CourierPR/ -- Medicenna Therapeutics, a clinical-stage immunotherapy company, announced that an abstract evaluating survival outcomes with bizaxofusp (formerly MDNA55) in unresectable, IDH-wildtype recurrent glioblastoma (rGBM) has been selected for an oral presentation at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO 2026), taking place from November 12-15, 2026, in Philadelphia.

The oral presentation, scheduled for Friday, November 13, 2026, at 10:36 a.m. Eastern Time, will be delivered by Dr. Nicholas A. Butowski, Professor of Neurological Surgery and Director of Translational Research, Neuro-Oncology at the University of California, San Francisco. The presentation will focus on survival outcomes with bizaxofusp in the intended Phase 3 population, using a propensity score-weighted external control arm (ECA).

Bizaxofusp, a targeted IL-4 Empowered Superkine, has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. The drug is designed to selectively target the interleukin-4 receptor (IL-4R), which is overexpressed by glioblastoma cells and cells in the tumor microenvironment. It is administered directly into the tumor using convection-enhanced delivery.

Dr. Fahar Merchant, President and Chief Executive Officer of Medicenna, expressed enthusiasm about the oral presentation.

Bizaxofusp has received Fast Track designation from the U.S. Food and Drug Administration and Orphan Drug designation in the United States and Europe. The drug has shown promise in treating glioblastoma, a highly aggressive form of brain cancer. The oral presentation is set to take place in Room 118 ABC, First Floor, Pennsylvania Convention Center, Philadelphia, on Friday, November 13, 2026, at 10:36 a.m. ET. A group Q&A session will follow at 10:43 a.m. ET.

Medicenna is also advancing other immunotherapy programs, including MDNA11, a long-acting IL-2 Superkine designed to selectively activate cancer-fighting immune cells. The company is currently evaluating MDNA11 in the Phase 1/2 ABILITY-1 study and the Phase 1b NEO-CYT study. Additionally, Medicenna is developing MDNA113, a targeted PD-1 x IL-2 bifunctional immunotherapy for solid tumors, and MDNA209, an antagonist of CD122 blocking IL-2/IL-15 signaling, using its proprietary BiSKIT and T-MASK platforms.

The oral presentation is a significant milestone for Medicenna and the neuro-oncology community. The results of the study could provide valuable insights into the efficacy of bizaxofusp in treating recurrent glioblastoma, potentially offering new treatment options for patients. The company's continued engagement with leading clinicians, researchers, and potential pharma partners during the meeting underscores its commitment to advancing the field of immunotherapy for cancer treatment.